Nikos Evangelou

Nikos Evangelou

Auto-generated profile, based on publicly available information

Nikos Evangelou

University of Nottingham

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ABAshley H Beecham
Ashley H Beecham
NPNikolaos A Patsopoulos
Nikolaos A Patsopoulos
DXDionysia K Xifara
Dionysia K Xifara
MDMary F Davis
Mary F Davis
AKAnu Kemppinen
Anu Kemppinen
JMJacob McCauley
Jacob McCauley
The International Multiple Sclerosis Genetics Consortium reports the discovery of 48 new susceptibility variants for multiple sclerosis through targeted follow-up of immune-related loci. They also report fine mapping of association signals at established susceptibility loci and provide insights into the immune system processes underlying this disease. Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 potentially associated regions (P < 1.0 × 10−4). In a replication phase, we combined these data with previous genome-wide association study (GWAS) data from an independent 14,802 subjects with multiple sclerosis and 26,703 healthy controls. In these 80,094 individuals of European ancestry, we identified 48 new susceptibility variants (P < 5.0 × 10−8), 3 of which we found after conditioning on previously identified variants. Thus, there are now 110 established multiple sclerosis risk variants at 103 discrete loci outside of the major histocompatibility complex. With high-resolution Bayesian fine mapping, we identified five regions where one variant accounted for more than 50% of the posterior probability of association. This study enhances the catalog of multiple sclerosis risk variants and illustrates the value of fine mapping in the resolution of GWAS signals.

1 April 2012 in The Lancet Neurology
Verified
Journal Article
Closed access
Massimo FilippiMassimo Filippi
Massimo Filippi
MRMaria A Rocca
Maria A Rocca
FBFrederik Barkhof
Frederik Barkhof
WBWolfgang Brück
Wolfgang Brück
JCJacqueline T Chen
Jacqueline T Chen
HLHans Lassmann
Hans Lassmann

1 January 2014 in NeuroImage
Verified
Journal Article
Open access
PSPatrick W. Stroman
Patrick W. Stroman
CWC. Wheeler-Kingshott
C. Wheeler-Kingshott
MBM. Bacon
M. Bacon
JSJ.M. Schwab
J.M. Schwab
RBR. Bosma
R. Bosma
ITI. Tracey
I. Tracey
A first-ever spinal cord imaging meeting was sponsored by the International Spinal Research Trust and the Wings for Life Foundation with the aim of identifying the current state-of-the-art of spinal cord imaging, the current greatest challenges, and greatest needs for future development. This meeting was attended by a small group of invited experts spanning all aspects of spinal cord imaging from basic research to clinical practice. The greatest current challenges for spinal cord imaging were identified as arising from the imaging environment itself; difficult imaging environment created by the bone surrounding the spinal canal, physiological motion of the cord and adjacent tissues, and small cross-sectional dimensions of the spinal cord, exacerbated by metallic implants often present in injured patients. Challenges were also identified as a result of a lack of "critical mass" of researchers taking on the development of spinal cord imaging, affecting both the rate of progress in the field, and the demand for equipment and software to manufacturers to produce the necessary tools. Here we define the current state-of-the-art of spinal cord imaging, discuss the underlying theory and challenges, and present the evidence for the current and potential power of these methods. In two review papers (part I and part II), we propose that the challenges can be overcome with advances in methods, improving availability and effectiveness of methods, and linking existing researchers to create the necessary scientific and clinical network to advance the rate of progress and impact of the research.

1 January 2014 in NeuroImage
Verified
Journal Article
Closed access
CWC.A. Wheeler-Kingshott
C.A. Wheeler-Kingshott
PSP.W. Stroman
P.W. Stroman
JSJ.M. Schwab
J.M. Schwab
MBM. Bacon
M. Bacon
RBR. Bosma
R. Bosma
ITI. Tracey
I. Tracey

8 February 2011 in Neurology
Verified
Journal Article
Closed access
PDF file
ETE.C. Tallantyre
E.C. Tallantyre
JDJ.E. Dixon
J.E. Dixon
IDI. Donaldson
I. Donaldson
TOT. Owens
T. Owens
PMP.S. Morgan
P.S. Morgan
NEN. Evangelou
N. Evangelou
Objectives: To investigate whether multiple sclerosis (MS) and non-MS white matter brain lesions can be distinguished by their appearance on 7 T T2*-weighted MRI. Methods: This was an observational study of 28 patients with MS and 17 patients with cerebral white matter lesions who did not have MS. Subjects were imaged using 7 T T2*-weighted imaging. White matter lesions were identified and analyzed for volume, location, and perivenous appearance. Results: Out of 901 lesions identified in patients with MS, 80% were perivenous. In comparison, 19% of 428 lesions identified in patients without MS had a perivenous appearance. Seven-Tesla T2*-weighted MRI reliably distinguished all patients with clinically definite MS (>40% lesions appeared perivenous) from those without clinical MS (<40% lesions appeared perivenous). Perivenous lesion appearance was more predictive of MS (odds ratio [OR] 14, p < 0.001) than subcortical or periventricular lesion location (OR 4.5, p < 0.001, and OR 2.4, p = 0.009). Perivenous lesion appearance was observed with a similar frequency in patients with clinically isolated syndrome of demyelination and in early (gadolinium-enhancing) MS lesions. Conclusion: Perivenous lesion location on 7 T T2*-weighted imaging is predictive of the presence of demyelination. Optimization of this imaging technique at lower magnetic resonance field strengths would offer benefit for the diagnosis of MS.

2 April 2013 in Neurology
Verified
Journal Article
Closed access
PDF file
LMLucy Matthews
Lucy Matthews
RMRita Marasco
Rita Marasco
MJMark Jenkinson
Mark Jenkinson
WKWilhelm Küker
Wilhelm Küker
SLSebastian Luppe
Sebastian Luppe
JPJacqueline Palace
Jacqueline Palace
Objective: Neuromyelitis optica and its spectrum disorder (NMOSD) can present similarly to relapsing-remitting multiple sclerosis (RRMS). Using a quantitative lesion mapping approach, this research aimed to identify differences in MRI brain lesion distribution between aquaporin-4 antibody–positive NMOSD and RRMS, and to test their diagnostic potential. Methods: Clinical brain MRI sequences for 44 patients with aquaporin-4 antibody–positive NMOSD and 50 patients with RRMS were examined for the distribution and morphology of brain lesions. T2 lesion maps were created for each subject allowing the quantitative comparison of the 2 conditions with lesion probability and voxel-wise analysis. Results: Sixty-three percent of patients with NMOSD had brain lesions and of these 27% were diagnostic of multiple sclerosis. Patients with RRMS were significantly more likely to have lesions adjacent to the body of the lateral ventricle than patients with NMOSD. Direct comparison of the probability distributions and the morphologic attributes of the lesions in each group identified criteria of “at least 1 lesion adjacent to the body of the lateral ventricle and in the inferior temporal lobe; or the presence of a subcortical U-fiber lesion; or a Dawson9s finger-type lesion,” which could distinguish patients with multiple sclerosis from those with NMOSD with 92% sensitivity, 96% specificity, 98% positive predictive value, and 86% negative predictive value. Conclusion: Careful inspection of the distribution and morphology of MRI brain lesions can distinguish RRMS and NMOSD.